Hence, to maximize the clinical benefit of ICI in EGFR-driven NSCLC, especially NSCLC resistant to EGFR-TKIs, it is essential to investigate the mechanisms by which EGFR-TKI resistance contributes to the development of an immunosuppressive microenvironment. Here, EGFR is linked to non-small cell lung carcinoma.